drugset
drugset / Trial / NCT04667572

Safety & Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution

NCT04667572 ↗

Phase 1 Completed 249 enrolled Cornea Associates of Texas
RandomizedParallel-groupOpen-labelTreatment

Summary

Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-linking in Eyes With Corneal Thinning Conditions

Timeline

Start
2021-02-01
Primary completion
2024-08-21
Completion
2024-08-21

Drugs

EvaluationDrugModalityDoseRoute
Background Riboflavin Other / unclassified — —

Indications

corneal degeneration corneal ectasia keratoconus pellucid marginal degeneration